AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19

AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19

AstraZeneca's experimental COVID-19 antibody drug cocktail succeeded in reducing severe disease or death in non-hospitalized patients in a late-stage study, the British drugmaker said on

AstraZeneca antibody cocktail could be used as jab alternative and treat Covid

The drug- called AZD7442 - was shown to decrease the chances of a Covid sufferer being hospitalised or dying by 67 per cent with the antibody also found to cut the risk of infected people showing key symptoms

Antibody Injection Cuts Severe COVID-19 Risk: AstraZeneca Study

An antibody combination treatment delivered through an injection has shown "statistically significant" reduction in severe Covid or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic Covid, AstraZeneca reported

AstraZeneca Covid antibody injection effective at reducing risk of severe illness or death from the virus, trial says

AstraZeneca has released new data from phase-three trials of its Covid-19 antibody injection, AZD7442, showing it reduces the risk of developing severe illness or death from the coronavirus in vulnerable people.

Covid-19 wrap: Vaccines proven effective, AstraZeneca touts antibody cocktail, Russia deaths surge

The novel coronavirus has killed at least 4 847 904 people since the outbreak emerged in China in December 2019, according to a tally from official sources compiled by AFP.

AstraZeneca COVID-19 drug prevents severe disease if given early, company says - National

The risk reduction was even better in patients who started therapy within just five days of initial symptoms, said company AstraZeneca.